TICKERNERD
Menu
VTAKVTAKHealthcare · Medical Devices

VTAK Stock Forecast: Catheter Precision, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$0.26
+5.52% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$905,977.00
Ticker Nerd rank
28 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−9.0%
1M
−66.6%
YTD
−85.6%
1Y
−91.8%
From 52W high
−93.8%
From 52W low
+5.5%
$0.25
$4.25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VTAK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Catheter Precision, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
100
Growth
98
Accruals
58
Quality
40
Momentum
29
Revisions
25
Volatility
18
Issuance
11
Value
5

Size (100): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own Catheter Precision, Inc. — and when they’d sell — is the membership.

Wall Street

VTAK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VTAK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26VTAK

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first

Of the 14 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
21 Oct 2021HC Wainwright & Co.InitiatesBuy$12
17 Mar 2021Maxim GroupDowngradeHold—
25 Nov 2020Cantor FitzgeraldMaintainsNeutral—
25 Nov 2020Piper JaffrayDowngradeNeutral—
25 Nov 2020Piper SandlerMaintainsNeutral—
25 Nov 2020PiperJaffrayInitiatesOverweight—
25 Nov 2020SunTrust Robinson HumphreyInitiatesBuy—
14 May 2020Piper SandlerMaintainsNeutral$1.50 → $1.00
11 Mar 2020Cantor FitzgeraldMaintainsNeutral$2.00 → $1.50
13 Aug 2019Piper JaffrayDowngradeNeutral—
13 Aug 2019Piper SandlerDowngradeNeutral$9.00 → $1.50
22 Oct 2018Cantor FitzgeraldInitiatesOverweight—
22 Oct 2018PiperJaffrayInitiatesOverweight—
22 Oct 2018SunTrust Robinson HumphreyInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

VTAK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Catheter Precision, Inc. (VTAK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 73% of US stocks

Price / sales
0.8×

Cheaper than 74% of US stocks

Price / book
0.1×

Cheaper than 91% of US stocks

EV / EBITDA
−1.3×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
202.1%

Higher than 96% of US stocks

Earnings growth (YoY)
202.1%

Higher than 91% of US stocks

Gross margin
90.3%

Higher than 97% of US stocks

Operating margin
−536.6%

Higher than 8% of US stocks

Net margin
92.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−179.7%

Higher than 7% of US stocks

Return on assets
−23.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VTAK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VTAKCatheter Precision, Inc.$905,977.00
28
BJDXBluejay Diagnostics, Inc.$889,900.00
21
NUWENuwellis, Inc.$633,900.00
24
PFSAProfusa, Inc.$561,800.00
8
AEMDAethlon Medical, Inc.$1.7M
23
IVFINVO Fertility, Inc.$2.1M
47
FEEDENvue Medical, Inc.$2.9M
25
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTAK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest VTAK news & analysis

Flyte Partners with LDV at The Maidstone to Elevate Luxury Travel to the Hamptons

GlobeNewsWire · 29 July 2026positive

Flyte, a subsidiary of Catheter Precision, Inc. (VTAK), announced a strategic partnership with The Maidstone hotel in the Hamptons to offer guests access and savings on Flyte's private aviation services.

Why it matters — This partnership expands VTAK's Flyte subsidiary into luxury hospitality, potentially opening a new revenue channel by connecting private aviation services with high-end travel.

FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner

GlobeNewsWire · 27 July 2026neutral

FLYTE announced a partnership with 319 Golf Society, becoming its exclusive private aviation partner, offering preferred benefits to members of premier private golf clubs across the United States.

Why it matters — The text does not mention Catheter Precision, Inc. (VTAK) or any connection to its business, so the relevance to VTAK watchers is unclear from this item alone.

FAQ

Frequently asked questions about VTAK stock

Is VTAK stock a buy right now?

Of the 1 analysts covering Catheter Precision, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Catheter Precision, Inc. 28 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VTAK?

As at 1 Aug 2026, Catheter Precision, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

What is the VTAK stock forecast for 2030?

No analyst covering Catheter Precision, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTAK are extrapolating price history, which says nothing about the business.

How has VTAK stock performed over the past year?

Catheter Precision, Inc. returned -91.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Catheter Precision, Inc. do?

Catheter Precision, Inc. is a dynamic player in the medical technology sector, specializing in the development and commercialization of advanced catheters and related technologies.

What is the latest news on VTAK?

The most recent item we track (GlobeNewsWire, 29 July 2026): "Flyte Partners with LDV at The Maidstone to Elevate Luxury Travel to the Hamptons". Flyte, a subsidiary of Catheter Precision, Inc. (VTAK), announced a strategic partnership with The Maidstone hotel in the Hamptons to offer guests access and savings on Flyte's private aviation services.

Company

About Catheter Precision, Inc.

Catheter Precision, Inc. is a dynamic player in the medical technology sector, specializing in the development and commercialization of advanced catheters and related technologies. The company focuses on providing innovative solutions for electrophysiology, a branch of cardiology that examines and treats arrhythmias. Their products are designed to support physicians in diagnosing and treating heart rhythm disorders with precision and efficacy. Notable features of Catheter Precision’s offerings include cutting-edge technology that enhances the accuracy of cardiac interventions and improves patient outcomes. As part of the broader healthcare sector, the company contributes to advancing medical treatments and has a significant impact on the quality of care provided to patients with cardiac issues. By continually innovating and integrating state-of-the-art technologies, Catheter Precision plays a crucial role in the electrophysiology market, offering tools that empower healthcare professionals to deliver superior cardiac care.

CEO Mr. David A. Jenkins · 17 employees · United States · https://www.catheterprecision.com